Simple Summary Oncolytic viruses (OVs) are viruses that selectively target and kill cancer
cells while sparing normal ones. OVs are from diverse families of viruses, but naturally …

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted
therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered …

Purpose The percentage of patients with metastatic non-small cell lung cancer (NSCLC) and
melanoma who benefit from anti–programmed cell death protein 1 (anti-PD-1) is low owing …

Simple Summary Monoclonal antibodies are increasingly used for a broad range of
diseases. Rising demand must face with time time-consuming and laborious processes to …

Background Lung cancer is the leading cause of cancer-related death worldwide, with non-
small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has …

Recently, modern therapies involving immune checkpoint inhibitors, cytokines, and oncolytic
virus have been developed. Because of the limited treatment effect of modern therapy alone …

Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for
approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early …

Cancer treatment is gradually entering an era of precision, with multitude studies in gene
testing and immunotherapy. Tumor cells can be recognized and eliminated by the immune …

Lung adenocarcinoma (LUAD) is the most common and lethal cancer worldwide.
Radiotherapy (RT) is widely used at all stages of LUAD, and the development of …

Non-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only
effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical …